B Braun's profits fall 12% in 1996
This article was originally published in Clinica
German healthcare company B Braun Melsungen saw total sales rise 6% to DM 3,172 million ($2,115 million) in 1996. Net profits, however, fell 12% compared with an increase of 18% last year. The company attributes the fall in profitability to price pressures in its main market, Europe, which accounts for over 70% of total sales. Sales increases were recorded in South America and Asia, while the US, France and Germany experienced the highest sales losses, mainly through falling prices.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.